A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*
暂无分享,去创建一个
Nan Wang | Natalie G. Ahn | William M. Old | Thomas Lee | N. Ahn | S. Stuart | W. Old | S. Houel | Stephane Houel | Scott A. Stuart | Nan Wang | Thomas Lee
[1] N. Colburn,et al. Transactivation of Fra-1 and Consequent Activation of AP-1 Occur Extracellular Signal-Regulated Kinase Dependently , 2002, Molecular and Cellular Biology.
[2] E. Collisson,et al. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. , 2003, Cancer research.
[3] James R. Woodgett,et al. Phosphorylation of c-jun mediated by MAP kinases , 1991, Nature.
[4] D. Peeper,et al. Antagonistic TSC22D1 variants control BRAFE600‐induced senescence , 2011, The EMBO journal.
[5] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[6] G. Barsh,et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .
[7] K. Resing,et al. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. , 2000, Molecular cell.
[8] M. Herlyn,et al. The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.
[9] B. Snel,et al. STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. , 2000, Nucleic acids research.
[10] M. Mann,et al. Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics , 2009, Molecular & Cellular Proteomics.
[11] J. Asara,et al. Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. , 2010, Genes & development.
[12] R. Hipskind,et al. Ubiquitin-Independent Proteasomal Degradation of Fra-1 Is Antagonized by Erk1/2 Pathway-Mediated Phosphorylation of a Unique C-Terminal Destabilizer , 2007, Molecular and Cellular Biology.
[13] Ming Zhou,et al. Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.
[14] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[15] M. Mann,et al. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC) , 2006, Nature Protocols.
[16] Hiderou Yoshida,et al. ATF6 Activated by Proteolysis Binds in the Presence of NF-Y (CBF) Directly to the cis-Acting Element Responsible for the Mammalian Unfolded Protein Response , 2000, Molecular and Cellular Biology.
[17] Kate Owen,et al. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2016, eLife.
[18] Christian von Mering,et al. STRING 7—recent developments in the integration and prediction of protein interactions , 2006, Nucleic Acids Res..
[19] C. Gretzmeier,et al. Rapid combinatorial ERLIC-SCX solid-phase extraction for in-depth phosphoproteome analysis. , 2013, Journal of proteome research.
[20] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[21] Candace R. Chouinard,et al. Large-Scale Discovery of ERK2 Substrates Identifies ERK-Mediated Transcriptional Regulation by ETV3 , 2011, Science Signaling.
[22] Peter Rodgers,et al. eulerAPE: Drawing Area-Proportional 3-Venn Diagrams Using Ellipses , 2014, PloS one.
[23] S. Lemieux,et al. Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions , 2013, Molecular systems biology.
[24] T. Curran,et al. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation. Characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. , 1991, The Journal of biological chemistry.
[25] P. Jennings,et al. The AD1 transactivation domain of E2A contains a highly conserved helix which is required for its activity in both Saccharomyces cerevisiae and mammalian cells , 1996, Molecular and cellular biology.
[26] W. Kolch,et al. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. , 2002, Journal of cell science.
[27] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[28] M. Molloy,et al. Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition , 2014, Molecular Cancer Therapeutics.
[29] Bin Zhang,et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..
[30] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[31] G. Linette,et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.
[32] P. Hersey,et al. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. , 2007, Cancer research.
[33] J. Blenis,et al. Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3 , 2014, Proceedings of the National Academy of Sciences.
[34] A. Aplin,et al. Resistance to RAF inhibitors revisited , 2013, The Journal of investigative dermatology.
[35] W. Lim,et al. Systematic Functional Prioritization of Protein Posttranslational Modifications , 2012, Cell.
[36] K. Resing,et al. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. , 2009, Molecular cell.
[37] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[38] P. LoRusso,et al. Clinical experience of MEK inhibitors in cancer therapy. , 2007, Biochimica et biophysica acta.
[39] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[40] A. V. D. Van Der Zee,et al. Multidimensional separation of tryptic peptides from human serum proteins using reversed-phase, strong cation exchange, weak anion exchange, and fused-core fluorinated stationary phases. , 2013, Journal of separation science.
[41] Anushya Muruganujan,et al. Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.
[42] G. Robertson,et al. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. , 2004, Gene.
[43] C. Gretzmeier,et al. Combinatorial use of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) and strong cation exchange (SCX) chromatography for in-depth phosphoproteome analysis. , 2012, Journal of proteome research.
[44] E. Nishida,et al. Phosphoproteomics reveals new ERK MAP kinase targets and links ERK to nucleoporin-mediated nuclear transport , 2009, Nature Structural &Molecular Biology.
[45] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[46] F. Collins,et al. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines , 1993, Nature Genetics.
[47] C. Gretzmeier,et al. Comparison of ERLIC-TiO2, HILIC-TiO2, and SCX-TiO2 for global phosphoproteomics approaches. , 2011, Journal of proteome research.
[48] M. Montminy,et al. The CREB Coactivator CRTC2 Links Hepatic ER Stress and Fasting Gluconeogenesis , 2009, Nature.
[49] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[50] S. Lim,et al. A comparative study of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) versus SCX-IMAC-based methods for phosphopeptide isolation/enrichment. , 2008, Journal of proteome research.
[51] Tyson V. Sharp,et al. LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[52] Andrew R. Jones,et al. ProteomeXchange provides globally co-ordinated proteomics data submission and dissemination , 2014, Nature Biotechnology.
[53] M. Mann,et al. Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.
[54] R. Sullivan,et al. The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be , 2013, Clinical Cancer Research.
[55] P. Hersey,et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. , 2008, Cancer research.
[56] R. Roskoski. MEK1/2 dual-specificity protein kinases: structure and regulation. , 2012, Biochemical and biophysical research communications.
[57] Alex Sánchez-Pla,et al. PTOV1 is overexpressed in human high-grade malignant tumors , 2011, Virchows Archiv.
[58] C. Eyers. Universal sample preparation method for proteome analysis , 2009 .
[59] C. Slaughter,et al. ERK phosphorylation potentiates Elk‐1‐mediated ternary complex formation and transactivation. , 1995, The EMBO journal.
[60] Lanju Zhang,et al. A New Bliss Independence Model to Analyze Drug Combination Data , 2014, Journal of biomolecular screening.
[61] Ian G. Cowell,et al. Transcriptional repression by the human bZIP factor E4BP4: definition of a minimal repression domain , 1994, Nucleic Acids Res..
[62] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[63] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[64] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[65] W. Kolch,et al. Raf family kinases: old dogs have learned new tricks. , 2011, Genes & cancer.
[66] K. Shokat,et al. Identification of Novel ERK2 Substrates through Use of an Engineered Kinase and ATP Analogs* , 2003, The Journal of Biological Chemistry.
[67] X. Estivill,et al. PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks , 2001, Oncogene.
[68] P. Bork,et al. Evolution and functional cross‐talk of protein post‐translational modifications , 2013, Molecular systems biology.
[69] V. Sondak,et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.
[70] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[71] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[72] D. Baldwin,et al. RIP2 Is a Raf1-activated Mitogen-activated Protein Kinase Kinase* , 1999, The Journal of Biological Chemistry.
[73] R. Seger,et al. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.